12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bioniche, Endo deal

Bioniche said Endo's Endo Pharmaceuticals subsidiary completed all Urocidin termination activities and officially returned clinical trial sponsorship for the bladder cancer compound to Bioniche. Last December, Bioniche said Endo's subsidiary returned its exclusive, worldwide rights to Bioniche. On Jan. 3, Bioniche provided an update stating that...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >